On January 14th 2013, the results of the International Consortium on Acute Promyelocytic Leukemia (IC-APL) (1) In order to participate in the IC-APL, countries had to fulfill minimum requirements, which included availability of drugs, pre-existing transfusion medicine services, a hematology lab capable of performing basic fluorescence microscopy and ability to report data and participate in meetings using web tools. APL was selected as a model disease to test the hypothesis that networking is an effective strategy to improve the outcome of patients with hematological malignancies in developing countries. The main reasons that guided this choice were: a) APL has become a highly curable disease since the introduction of combination therapy with alltrans retinoic acid (ATRA) and anthracycline-based chemotherapy, b) ATRA is of relatively low cost and available in the four developing countries, and c) the prompt diagnosis and immediate introduction of therapy can revert the coagulation abnormalities common in the disease and associated with high mortality rates due to bleeding.
In order to perform a prompt diagnosis and the immediate introduction of ATRA, the IC-APL adopted the anti-PML immunofluorescence staining test which was developed by Falini et al. (2) and requires minimal infrastructure. This test is based on the molecular pathogenesis of APL, which is characterized by its association with chromosomal translocations involving the loci of the Promyelocytic Leukemia (PML) and Retinoic Acid Receptor Alpha (RARa) genes on chromosomes 15 and 17, respectively. The PML-RARA fusion protein retains most of the functional domains of the parental proteins and interacts with several proteins in the nucleus, in particular with the native PML causing its delocalization from the nuclear body (3) . As a consequence, in APL cells, the PML protein is dispersed throughout the nucleus and generates a microspeckled pattern identifiable by the immunofluorescence staining test using the anti-PML (PG-M3) antibody (Figure 1 ). Yet the introduction of a method for rapid diagnosis was only one of the items in the IC-APL strategy. By fostering collaboration between researchers, clinicians, and laboratory scientists from institutions in developing countries and wellestablished international cooperative groups based in the United States and in Europe, the IC-APL group generated guidelines, trained personnel, developed medical educational material, facilitated lab research and enforced requests to health authorities to guarantee ATRA availability.
The formulated treatment guidelines, based on the experience of the Spanish group, PETHEMA (4) , were adapted to local conditions and resources. An important change in the induction therapy protocol in the IC-APL study was the replacement of the commonly used anthracycline idarubicin with the less expensive and more readily available daunorubicin. The guidelines also covered standardized approaches for supportive care and disease follow-up measures. Throughout the trial, participating sites registered all cases using common clinical record forms in the Pediatric Oncology Network Database (POND) and collaborated with national clinical trial coordinators and reference laboratories to confirm the integrity and accuracy of treatment data.
The results of the study were remarkable, of 180 evaluable patients, 153 (85%) achieved complete hematological remission. Twenty-seven patients (15%) died during induction (early death). About 90% of all patients who achieved complete remission were alive at the time of analysis, five (2.6%) were lost to follow-up and ten (5.2%) died in complete remission. There was one case of molecular persistence of the PML/RARA rearrangement after consolidation and there were nine relapses, of which four were molecular relapses. The 2-year overall survival and diseasefree survival were 80% (95% confidence interval: 73% -85%) and 91% (95% confidence interval: 86% -95%), respectively. The 2-year cumulative incidence of relapse was 4.5% (95% confidence interval: 1.8%-9.2%). The results are comparable to those reported in the US (5) and Europe (4, 6) and represent a nearly 50% decrease in early mortality and a nearly 30% improvement in overall survival compared to historical controls (7) . It is important to stress that there is a disparity between reported outcomes, particularly in hemorrhagic-related death rates, in clinical trials as compared to population based studies. In the study by Park et al. (8) the death rate within one month of APL diagnosis was 17.3%. Likewise, Lehmann et al. (9) reported the outcomes of APL patients registered in the population-based Swedish Adult Acute Leukemia Registry between 1997 and 2006 with calculated death rates of 26% and 29% within 14 and 30 days of diagnosis, respectively.
Taken together, the results reported by the IC-APL demonstrate that international networking is an effective strategy to change the reality of treatment of patients with hematological malignancies in developing countries. In addition, it was an opportunity for Brazilian hematologists to strengthen ties, exchange experiences and consolidate the position of the country in the international scientific scenario.
